nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanabenz—Infusion related reaction—Capecitabine—esophageal cancer	0.0521	0.062	CcSEcCtD
Guanabenz—Skin fissures—Capecitabine—esophageal cancer	0.0468	0.0557	CcSEcCtD
Guanabenz—Fluid overload—Carboplatin—esophageal cancer	0.0365	0.0435	CcSEcCtD
Guanabenz—Infusion site pain—Capecitabine—esophageal cancer	0.0299	0.0356	CcSEcCtD
Guanabenz—Ascites—Capecitabine—esophageal cancer	0.0108	0.0129	CcSEcCtD
Guanabenz—Fluid overload—Cisplatin—esophageal cancer	0.0107	0.0128	CcSEcCtD
Guanabenz—Prurigo—Capecitabine—esophageal cancer	0.0106	0.0127	CcSEcCtD
Guanabenz—Swelling face—Capecitabine—esophageal cancer	0.0103	0.0123	CcSEcCtD
Guanabenz—Balance disorder—Capecitabine—esophageal cancer	0.00898	0.0107	CcSEcCtD
Guanabenz—Gastric ulcer—Capecitabine—esophageal cancer	0.00845	0.0101	CcSEcCtD
Guanabenz—Ageusia—Cisplatin—esophageal cancer	0.00822	0.00979	CcSEcCtD
Guanabenz—Infection—Carboplatin—esophageal cancer	0.00805	0.00959	CcSEcCtD
Guanabenz—Raised liver function tests—Methotrexate—esophageal cancer	0.00792	0.00943	CcSEcCtD
Guanabenz—Hypomagnesaemia—Capecitabine—esophageal cancer	0.00773	0.0092	CcSEcCtD
Guanabenz—Nail disorder—Capecitabine—esophageal cancer	0.00757	0.00902	CcSEcCtD
Guanabenz—Furuncle—Methotrexate—esophageal cancer	0.00745	0.00888	CcSEcCtD
Guanabenz—Appetite absent—Methotrexate—esophageal cancer	0.00735	0.00875	CcSEcCtD
Guanabenz—Intestinal obstruction—Capecitabine—esophageal cancer	0.0072	0.00858	CcSEcCtD
Guanabenz—Hypercalcaemia—Capecitabine—esophageal cancer	0.00707	0.00842	CcSEcCtD
Guanabenz—Ileus—Capecitabine—esophageal cancer	0.00694	0.00826	CcSEcCtD
Guanabenz—Pain—Carboplatin—esophageal cancer	0.00693	0.00825	CcSEcCtD
Guanabenz—Blister—Capecitabine—esophageal cancer	0.00681	0.00811	CcSEcCtD
Guanabenz—Hiccups—Cisplatin—esophageal cancer	0.00666	0.00793	CcSEcCtD
Guanabenz—Body temperature increased—Carboplatin—esophageal cancer	0.00641	0.00763	CcSEcCtD
Guanabenz—Skin exfoliation—Cisplatin—esophageal cancer	0.00636	0.00757	CcSEcCtD
Guanabenz—Skin ulcer—Capecitabine—esophageal cancer	0.00631	0.00751	CcSEcCtD
Guanabenz—Ageusia—Capecitabine—esophageal cancer	0.00606	0.00722	CcSEcCtD
Guanabenz—Psoriasis—Methotrexate—esophageal cancer	0.00582	0.00693	CcSEcCtD
Guanabenz—Nail disorder—Methotrexate—esophageal cancer	0.00564	0.00671	CcSEcCtD
Guanabenz—Skin discolouration—Capecitabine—esophageal cancer	0.00544	0.00647	CcSEcCtD
Guanabenz—Hypocalcaemia—Capecitabine—esophageal cancer	0.00536	0.00639	CcSEcCtD
Guanabenz—Burning sensation—Methotrexate—esophageal cancer	0.00526	0.00627	CcSEcCtD
Guanabenz—Lung disorder—Methotrexate—esophageal cancer	0.00517	0.00615	CcSEcCtD
Guanabenz—Bone pain—Capecitabine—esophageal cancer	0.00513	0.0061	CcSEcCtD
Guanabenz—Inflammation—Capecitabine—esophageal cancer	0.00506	0.00603	CcSEcCtD
Guanabenz—Neck pain—Capecitabine—esophageal cancer	0.00497	0.00592	CcSEcCtD
Guanabenz—Hiccups—Capecitabine—esophageal cancer	0.00491	0.00585	CcSEcCtD
Guanabenz—Hyponatraemia—Cisplatin—esophageal cancer	0.00486	0.00578	CcSEcCtD
Guanabenz—Skin ulcer—Methotrexate—esophageal cancer	0.0047	0.00559	CcSEcCtD
Guanabenz—Skin exfoliation—Capecitabine—esophageal cancer	0.00469	0.00558	CcSEcCtD
Guanabenz—Face oedema—Cisplatin—esophageal cancer	0.00467	0.00556	CcSEcCtD
Guanabenz—Dehydration—Cisplatin—esophageal cancer	0.0045	0.00536	CcSEcCtD
Guanabenz—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00442	0.00526	CcSEcCtD
Guanabenz—Hypokalaemia—Cisplatin—esophageal cancer	0.0044	0.00524	CcSEcCtD
Guanabenz—Breast disorder—Cisplatin—esophageal cancer	0.00437	0.0052	CcSEcCtD
Guanabenz—Cramp muscle—Cisplatin—esophageal cancer	0.00436	0.00519	CcSEcCtD
Guanabenz—Mental disability—Capecitabine—esophageal cancer	0.00426	0.00507	CcSEcCtD
Guanabenz—Diabetes mellitus—Capecitabine—esophageal cancer	0.0041	0.00488	CcSEcCtD
Guanabenz—Skin discolouration—Methotrexate—esophageal cancer	0.00405	0.00482	CcSEcCtD
Guanabenz—Abdominal discomfort—Cisplatin—esophageal cancer	0.00401	0.00477	CcSEcCtD
Guanabenz—Oliguria—Methotrexate—esophageal cancer	0.00397	0.00472	CcSEcCtD
Guanabenz—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.00378	0.0045	CcSEcCtD
Guanabenz—Inflammation—Methotrexate—esophageal cancer	0.00377	0.00449	CcSEcCtD
Guanabenz—Vasculitis—Methotrexate—esophageal cancer	0.00375	0.00446	CcSEcCtD
Guanabenz—Dermatitis bullous—Capecitabine—esophageal cancer	0.00373	0.00444	CcSEcCtD
Guanabenz—Cardiac failure—Capecitabine—esophageal cancer	0.00365	0.00435	CcSEcCtD
Guanabenz—Hyponatraemia—Capecitabine—esophageal cancer	0.00358	0.00426	CcSEcCtD
Guanabenz—Skin exfoliation—Methotrexate—esophageal cancer	0.00349	0.00416	CcSEcCtD
Guanabenz—Face oedema—Capecitabine—esophageal cancer	0.00344	0.0041	CcSEcCtD
Guanabenz—Dehydration—Capecitabine—esophageal cancer	0.00332	0.00395	CcSEcCtD
Guanabenz—Liver function test abnormal—Capecitabine—esophageal cancer	0.00329	0.00392	CcSEcCtD
Guanabenz—Connective tissue disorder—Cisplatin—esophageal cancer	0.00329	0.00391	CcSEcCtD
Guanabenz—Dry skin—Capecitabine—esophageal cancer	0.00327	0.00389	CcSEcCtD
Guanabenz—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00326	0.00388	CcSEcCtD
Guanabenz—Pulmonary oedema—Methotrexate—esophageal cancer	0.00325	0.00387	CcSEcCtD
Guanabenz—Hypokalaemia—Capecitabine—esophageal cancer	0.00324	0.00386	CcSEcCtD
Guanabenz—Breast disorder—Capecitabine—esophageal cancer	0.00322	0.00384	CcSEcCtD
Guanabenz—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00321	0.00382	CcSEcCtD
Guanabenz—Gastritis—Capecitabine—esophageal cancer	0.00316	0.00376	CcSEcCtD
Guanabenz—Eye disorder—Cisplatin—esophageal cancer	0.00313	0.00372	CcSEcCtD
Guanabenz—Tinnitus—Cisplatin—esophageal cancer	0.00312	0.00371	CcSEcCtD
Guanabenz—Abdominal distension—Capecitabine—esophageal cancer	0.0031	0.00369	CcSEcCtD
Guanabenz—Influenza—Capecitabine—esophageal cancer	0.00308	0.00367	CcSEcCtD
Guanabenz—Diabetes mellitus—Methotrexate—esophageal cancer	0.00305	0.00363	CcSEcCtD
Guanabenz—Bronchospasm—Capecitabine—esophageal cancer	0.00303	0.00361	CcSEcCtD
Guanabenz—Immune system disorder—Cisplatin—esophageal cancer	0.00302	0.0036	CcSEcCtD
Guanabenz—Mediastinal disorder—Cisplatin—esophageal cancer	0.00302	0.00359	CcSEcCtD
Guanabenz—Abdominal discomfort—Capecitabine—esophageal cancer	0.00295	0.00352	CcSEcCtD
Guanabenz—Erythema—Cisplatin—esophageal cancer	0.00291	0.00347	CcSEcCtD
Guanabenz—Malnutrition—Cisplatin—esophageal cancer	0.00291	0.00347	CcSEcCtD
Guanabenz—Flatulence—Cisplatin—esophageal cancer	0.00287	0.00342	CcSEcCtD
Guanabenz—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00286	0.00341	CcSEcCtD
Guanabenz—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00281	0.00335	CcSEcCtD
Guanabenz—Weight increased—Capecitabine—esophageal cancer	0.0028	0.00334	CcSEcCtD
Guanabenz—Muscle spasms—Cisplatin—esophageal cancer	0.0028	0.00333	CcSEcCtD
Guanabenz—Weight decreased—Capecitabine—esophageal cancer	0.00279	0.00332	CcSEcCtD
Guanabenz—Hyperglycaemia—Capecitabine—esophageal cancer	0.00278	0.00331	CcSEcCtD
Guanabenz—Infestation—Capecitabine—esophageal cancer	0.00275	0.00327	CcSEcCtD
Guanabenz—Infestation NOS—Capecitabine—esophageal cancer	0.00275	0.00327	CcSEcCtD
Guanabenz—Vision blurred—Cisplatin—esophageal cancer	0.00274	0.00327	CcSEcCtD
Guanabenz—Ill-defined disorder—Cisplatin—esophageal cancer	0.0027	0.00322	CcSEcCtD
Guanabenz—Anaemia—Cisplatin—esophageal cancer	0.00269	0.00321	CcSEcCtD
Guanabenz—Malaise—Cisplatin—esophageal cancer	0.00263	0.00313	CcSEcCtD
Guanabenz—Leukopenia—Cisplatin—esophageal cancer	0.00261	0.0031	CcSEcCtD
Guanabenz—Myalgia—Cisplatin—esophageal cancer	0.00248	0.00295	CcSEcCtD
Guanabenz—Haemoglobin—Capecitabine—esophageal cancer	0.00248	0.00295	CcSEcCtD
Guanabenz—Anxiety—Cisplatin—esophageal cancer	0.00247	0.00294	CcSEcCtD
Guanabenz—Haemorrhage—Capecitabine—esophageal cancer	0.00247	0.00294	CcSEcCtD
Guanabenz—Liver function test abnormal—Methotrexate—esophageal cancer	0.00245	0.00292	CcSEcCtD
Guanabenz—Discomfort—Cisplatin—esophageal cancer	0.00245	0.00292	CcSEcCtD
Guanabenz—Oedema peripheral—Capecitabine—esophageal cancer	0.00243	0.00289	CcSEcCtD
Guanabenz—Connective tissue disorder—Capecitabine—esophageal cancer	0.00242	0.00289	CcSEcCtD
Guanabenz—Breast disorder—Methotrexate—esophageal cancer	0.0024	0.00286	CcSEcCtD
Guanabenz—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00239	0.00285	CcSEcCtD
Guanabenz—Oedema—Cisplatin—esophageal cancer	0.00238	0.00283	CcSEcCtD
Guanabenz—Infection—Cisplatin—esophageal cancer	0.00236	0.00281	CcSEcCtD
Guanabenz—Erythema multiforme—Capecitabine—esophageal cancer	0.00233	0.00278	CcSEcCtD
Guanabenz—Nervous system disorder—Cisplatin—esophageal cancer	0.00233	0.00278	CcSEcCtD
Guanabenz—Thrombocytopenia—Cisplatin—esophageal cancer	0.00233	0.00277	CcSEcCtD
Guanabenz—Tachycardia—Cisplatin—esophageal cancer	0.00232	0.00276	CcSEcCtD
Guanabenz—Skin disorder—Cisplatin—esophageal cancer	0.00231	0.00275	CcSEcCtD
Guanabenz—Eye disorder—Capecitabine—esophageal cancer	0.0023	0.00274	CcSEcCtD
Guanabenz—Tinnitus—Capecitabine—esophageal cancer	0.0023	0.00274	CcSEcCtD
Guanabenz—Anorexia—Cisplatin—esophageal cancer	0.00227	0.0027	CcSEcCtD
Guanabenz—Immune system disorder—Capecitabine—esophageal cancer	0.00223	0.00265	CcSEcCtD
Guanabenz—Mediastinal disorder—Capecitabine—esophageal cancer	0.00222	0.00265	CcSEcCtD
Guanabenz—Hypotension—Cisplatin—esophageal cancer	0.00222	0.00264	CcSEcCtD
Guanabenz—Chills—Capecitabine—esophageal cancer	0.00221	0.00263	CcSEcCtD
Guanabenz—Abdominal discomfort—Methotrexate—esophageal cancer	0.0022	0.00262	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00217	0.00258	CcSEcCtD
Guanabenz—Malnutrition—Capecitabine—esophageal cancer	0.00215	0.00256	CcSEcCtD
Guanabenz—Erythema—Capecitabine—esophageal cancer	0.00215	0.00256	CcSEcCtD
Guanabenz—Paraesthesia—Cisplatin—esophageal cancer	0.00213	0.00254	CcSEcCtD
Guanabenz—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00213	0.00254	CcSEcCtD
Guanabenz—Dyspnoea—Cisplatin—esophageal cancer	0.00212	0.00252	CcSEcCtD
Guanabenz—Flatulence—Capecitabine—esophageal cancer	0.00212	0.00252	CcSEcCtD
Guanabenz—Back pain—Capecitabine—esophageal cancer	0.00208	0.00247	CcSEcCtD
Guanabenz—Decreased appetite—Cisplatin—esophageal cancer	0.00207	0.00246	CcSEcCtD
Guanabenz—Muscle spasms—Capecitabine—esophageal cancer	0.00206	0.00246	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00205	0.00244	CcSEcCtD
Guanabenz—Infestation NOS—Methotrexate—esophageal cancer	0.00205	0.00244	CcSEcCtD
Guanabenz—Infestation—Methotrexate—esophageal cancer	0.00205	0.00244	CcSEcCtD
Guanabenz—Pain—Cisplatin—esophageal cancer	0.00203	0.00242	CcSEcCtD
Guanabenz—Vision blurred—Capecitabine—esophageal cancer	0.00202	0.00241	CcSEcCtD
Guanabenz—Ill-defined disorder—Capecitabine—esophageal cancer	0.00199	0.00237	CcSEcCtD
Guanabenz—Anaemia—Capecitabine—esophageal cancer	0.00198	0.00236	CcSEcCtD
Guanabenz—Feeling abnormal—Cisplatin—esophageal cancer	0.00196	0.00233	CcSEcCtD
Guanabenz—Malaise—Capecitabine—esophageal cancer	0.00194	0.00231	CcSEcCtD
Guanabenz—Syncope—Capecitabine—esophageal cancer	0.00193	0.00229	CcSEcCtD
Guanabenz—Leukopenia—Capecitabine—esophageal cancer	0.00192	0.00229	CcSEcCtD
Guanabenz—Loss of consciousness—Capecitabine—esophageal cancer	0.00189	0.00225	CcSEcCtD
Guanabenz—Body temperature increased—Cisplatin—esophageal cancer	0.00188	0.00224	CcSEcCtD
Guanabenz—Cough—Capecitabine—esophageal cancer	0.00187	0.00223	CcSEcCtD
Guanabenz—Hypertension—Capecitabine—esophageal cancer	0.00185	0.00221	CcSEcCtD
Guanabenz—Haemoglobin—Methotrexate—esophageal cancer	0.00185	0.0022	CcSEcCtD
Guanabenz—Haemorrhage—Methotrexate—esophageal cancer	0.00184	0.00219	CcSEcCtD
Guanabenz—Myalgia—Capecitabine—esophageal cancer	0.00183	0.00218	CcSEcCtD
Guanabenz—Arthralgia—Capecitabine—esophageal cancer	0.00183	0.00218	CcSEcCtD
Guanabenz—Chest pain—Capecitabine—esophageal cancer	0.00183	0.00218	CcSEcCtD
Guanabenz—Anxiety—Capecitabine—esophageal cancer	0.00182	0.00217	CcSEcCtD
Guanabenz—Discomfort—Capecitabine—esophageal cancer	0.00181	0.00215	CcSEcCtD
Guanabenz—Dry mouth—Capecitabine—esophageal cancer	0.00179	0.00213	CcSEcCtD
Guanabenz—Confusional state—Capecitabine—esophageal cancer	0.00177	0.0021	CcSEcCtD
Guanabenz—Oedema—Capecitabine—esophageal cancer	0.00175	0.00209	CcSEcCtD
Guanabenz—Hypersensitivity—Cisplatin—esophageal cancer	0.00175	0.00209	CcSEcCtD
Guanabenz—Infection—Capecitabine—esophageal cancer	0.00174	0.00207	CcSEcCtD
Guanabenz—Erythema multiforme—Methotrexate—esophageal cancer	0.00174	0.00207	CcSEcCtD
Guanabenz—Shock—Capecitabine—esophageal cancer	0.00172	0.00205	CcSEcCtD
Guanabenz—Nervous system disorder—Capecitabine—esophageal cancer	0.00172	0.00205	CcSEcCtD
Guanabenz—Eye disorder—Methotrexate—esophageal cancer	0.00172	0.00204	CcSEcCtD
Guanabenz—Thrombocytopenia—Capecitabine—esophageal cancer	0.00172	0.00204	CcSEcCtD
Guanabenz—Tinnitus—Methotrexate—esophageal cancer	0.00171	0.00204	CcSEcCtD
Guanabenz—Tachycardia—Capecitabine—esophageal cancer	0.00171	0.00204	CcSEcCtD
Guanabenz—Asthenia—Cisplatin—esophageal cancer	0.00171	0.00203	CcSEcCtD
Guanabenz—Skin disorder—Capecitabine—esophageal cancer	0.0017	0.00203	CcSEcCtD
Guanabenz—Anorexia—Capecitabine—esophageal cancer	0.00167	0.00199	CcSEcCtD
Guanabenz—Immune system disorder—Methotrexate—esophageal cancer	0.00166	0.00197	CcSEcCtD
Guanabenz—Mediastinal disorder—Methotrexate—esophageal cancer	0.00165	0.00197	CcSEcCtD
Guanabenz—Chills—Methotrexate—esophageal cancer	0.00165	0.00196	CcSEcCtD
Guanabenz—Hypotension—Capecitabine—esophageal cancer	0.00164	0.00195	CcSEcCtD
Guanabenz—Diarrhoea—Cisplatin—esophageal cancer	0.00163	0.00194	CcSEcCtD
Guanabenz—Erythema—Methotrexate—esophageal cancer	0.0016	0.0019	CcSEcCtD
Guanabenz—Malnutrition—Methotrexate—esophageal cancer	0.0016	0.0019	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.0016	0.0019	CcSEcCtD
Guanabenz—Paraesthesia—Capecitabine—esophageal cancer	0.00157	0.00187	CcSEcCtD
Guanabenz—Dyspnoea—Capecitabine—esophageal cancer	0.00156	0.00186	CcSEcCtD
Guanabenz—Back pain—Methotrexate—esophageal cancer	0.00155	0.00184	CcSEcCtD
Guanabenz—Dyspepsia—Capecitabine—esophageal cancer	0.00154	0.00184	CcSEcCtD
Guanabenz—Decreased appetite—Capecitabine—esophageal cancer	0.00152	0.00181	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00151	0.0018	CcSEcCtD
Guanabenz—Vomiting—Cisplatin—esophageal cancer	0.00151	0.0018	CcSEcCtD
Guanabenz—Fatigue—Capecitabine—esophageal cancer	0.00151	0.0018	CcSEcCtD
Guanabenz—Vision blurred—Methotrexate—esophageal cancer	0.00151	0.00179	CcSEcCtD
Guanabenz—Rash—Cisplatin—esophageal cancer	0.0015	0.00178	CcSEcCtD
Guanabenz—Pain—Capecitabine—esophageal cancer	0.0015	0.00178	CcSEcCtD
Guanabenz—Constipation—Capecitabine—esophageal cancer	0.0015	0.00178	CcSEcCtD
Guanabenz—Dermatitis—Cisplatin—esophageal cancer	0.0015	0.00178	CcSEcCtD
Guanabenz—Ill-defined disorder—Methotrexate—esophageal cancer	0.00148	0.00177	CcSEcCtD
Guanabenz—Anaemia—Methotrexate—esophageal cancer	0.00148	0.00176	CcSEcCtD
Guanabenz—Feeling abnormal—Capecitabine—esophageal cancer	0.00144	0.00172	CcSEcCtD
Guanabenz—Malaise—Methotrexate—esophageal cancer	0.00144	0.00172	CcSEcCtD
Guanabenz—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00143	0.00171	CcSEcCtD
Guanabenz—Leukopenia—Methotrexate—esophageal cancer	0.00143	0.0017	CcSEcCtD
Guanabenz—Nausea—Cisplatin—esophageal cancer	0.00141	0.00168	CcSEcCtD
Guanabenz—Cough—Methotrexate—esophageal cancer	0.00139	0.00166	CcSEcCtD
Guanabenz—Urticaria—Capecitabine—esophageal cancer	0.00139	0.00166	CcSEcCtD
Guanabenz—Abdominal pain—Capecitabine—esophageal cancer	0.00139	0.00165	CcSEcCtD
Guanabenz—Body temperature increased—Capecitabine—esophageal cancer	0.00139	0.00165	CcSEcCtD
Guanabenz—Chest pain—Methotrexate—esophageal cancer	0.00136	0.00162	CcSEcCtD
Guanabenz—Myalgia—Methotrexate—esophageal cancer	0.00136	0.00162	CcSEcCtD
Guanabenz—Arthralgia—Methotrexate—esophageal cancer	0.00136	0.00162	CcSEcCtD
Guanabenz—Discomfort—Methotrexate—esophageal cancer	0.00134	0.0016	CcSEcCtD
Guanabenz—Confusional state—Methotrexate—esophageal cancer	0.00132	0.00157	CcSEcCtD
Guanabenz—Infection—Methotrexate—esophageal cancer	0.0013	0.00154	CcSEcCtD
Guanabenz—Hypersensitivity—Capecitabine—esophageal cancer	0.00129	0.00154	CcSEcCtD
Guanabenz—Nervous system disorder—Methotrexate—esophageal cancer	0.00128	0.00152	CcSEcCtD
Guanabenz—Thrombocytopenia—Methotrexate—esophageal cancer	0.00128	0.00152	CcSEcCtD
Guanabenz—Skin disorder—Methotrexate—esophageal cancer	0.00127	0.00151	CcSEcCtD
Guanabenz—Asthenia—Capecitabine—esophageal cancer	0.00126	0.0015	CcSEcCtD
Guanabenz—Anorexia—Methotrexate—esophageal cancer	0.00124	0.00148	CcSEcCtD
Guanabenz—Pruritus—Capecitabine—esophageal cancer	0.00124	0.00148	CcSEcCtD
Guanabenz—Hypotension—Methotrexate—esophageal cancer	0.00122	0.00145	CcSEcCtD
Guanabenz—Diarrhoea—Capecitabine—esophageal cancer	0.0012	0.00143	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00119	0.00141	CcSEcCtD
Guanabenz—Paraesthesia—Methotrexate—esophageal cancer	0.00117	0.00139	CcSEcCtD
Guanabenz—Dyspnoea—Methotrexate—esophageal cancer	0.00116	0.00138	CcSEcCtD
Guanabenz—Dizziness—Capecitabine—esophageal cancer	0.00116	0.00138	CcSEcCtD
Guanabenz—Dyspepsia—Methotrexate—esophageal cancer	0.00115	0.00137	CcSEcCtD
Guanabenz—Decreased appetite—Methotrexate—esophageal cancer	0.00113	0.00135	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00113	0.00134	CcSEcCtD
Guanabenz—Fatigue—Methotrexate—esophageal cancer	0.00112	0.00134	CcSEcCtD
Guanabenz—Pain—Methotrexate—esophageal cancer	0.00112	0.00133	CcSEcCtD
Guanabenz—Vomiting—Capecitabine—esophageal cancer	0.00111	0.00133	CcSEcCtD
Guanabenz—Rash—Capecitabine—esophageal cancer	0.0011	0.00132	CcSEcCtD
Guanabenz—Dermatitis—Capecitabine—esophageal cancer	0.0011	0.00131	CcSEcCtD
Guanabenz—Headache—Capecitabine—esophageal cancer	0.0011	0.00131	CcSEcCtD
Guanabenz—Feeling abnormal—Methotrexate—esophageal cancer	0.00107	0.00128	CcSEcCtD
Guanabenz—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00107	0.00127	CcSEcCtD
Guanabenz—Nausea—Capecitabine—esophageal cancer	0.00104	0.00124	CcSEcCtD
Guanabenz—Urticaria—Methotrexate—esophageal cancer	0.00104	0.00123	CcSEcCtD
Guanabenz—Abdominal pain—Methotrexate—esophageal cancer	0.00103	0.00123	CcSEcCtD
Guanabenz—Body temperature increased—Methotrexate—esophageal cancer	0.00103	0.00123	CcSEcCtD
Guanabenz—Hypersensitivity—Methotrexate—esophageal cancer	0.000961	0.00114	CcSEcCtD
Guanabenz—Asthenia—Methotrexate—esophageal cancer	0.000936	0.00111	CcSEcCtD
Guanabenz—Pruritus—Methotrexate—esophageal cancer	0.000923	0.0011	CcSEcCtD
Guanabenz—Diarrhoea—Methotrexate—esophageal cancer	0.000892	0.00106	CcSEcCtD
Guanabenz—Dizziness—Methotrexate—esophageal cancer	0.000863	0.00103	CcSEcCtD
Guanabenz—Vomiting—Methotrexate—esophageal cancer	0.000829	0.000987	CcSEcCtD
Guanabenz—Rash—Methotrexate—esophageal cancer	0.000822	0.000979	CcSEcCtD
Guanabenz—Dermatitis—Methotrexate—esophageal cancer	0.000822	0.000978	CcSEcCtD
Guanabenz—Headache—Methotrexate—esophageal cancer	0.000817	0.000973	CcSEcCtD
Guanabenz—Nausea—Methotrexate—esophageal cancer	0.000775	0.000922	CcSEcCtD
Guanabenz—ADRA2C—Metabolism—TYMP—esophageal cancer	0.000175	0.00109	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—WIF1—esophageal cancer	0.000174	0.00109	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—GNG7—esophageal cancer	0.000174	0.00109	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CSNK1A1—esophageal cancer	0.000172	0.00108	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—CXCL2—esophageal cancer	0.000171	0.00107	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—SST—esophageal cancer	0.000171	0.00107	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—ANXA1—esophageal cancer	0.000171	0.00107	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CYP26A1—esophageal cancer	0.00017	0.00106	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PLCE1—esophageal cancer	0.000169	0.00106	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ADH7—esophageal cancer	0.000169	0.00106	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000167	0.00104	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000167	0.00104	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—GHRL—esophageal cancer	0.000166	0.00104	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—ABL1—esophageal cancer	0.000166	0.00104	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PDE4D—esophageal cancer	0.000166	0.00104	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—SST—esophageal cancer	0.000166	0.00104	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—ALOX15—esophageal cancer	0.000166	0.00103	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—GHRL—esophageal cancer	0.000162	0.00101	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PFN1—esophageal cancer	0.000161	0.00101	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CSNK1A1—esophageal cancer	0.000161	0.001	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—ANXA1—esophageal cancer	0.000159	0.000995	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—GNG7—esophageal cancer	0.000158	0.000987	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GSTO1—esophageal cancer	0.000158	0.000987	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—TPI1—esophageal cancer	0.000158	0.000987	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—NOS2—esophageal cancer	0.000158	0.000987	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—SST—esophageal cancer	0.000155	0.000968	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—CXCL2—esophageal cancer	0.000153	0.000958	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—WWOX—esophageal cancer	0.000152	0.000951	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—ALDOB—esophageal cancer	0.000151	0.000946	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—GHRL—esophageal cancer	0.000151	0.000944	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PFN1—esophageal cancer	0.00015	0.00094	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ADH1B—esophageal cancer	0.000148	0.000927	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—NOS2—esophageal cancer	0.000148	0.000922	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GAPDH—esophageal cancer	0.000146	0.000911	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000145	0.000909	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—FKBP1A—esophageal cancer	0.000145	0.000905	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—ELMO1—esophageal cancer	0.000145	0.000904	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CRABP1—esophageal cancer	0.000145	0.000903	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—ANXA1—esophageal cancer	0.000143	0.00089	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—TYMP—esophageal cancer	0.000142	0.000886	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—CREBBP—esophageal cancer	0.000142	0.000886	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—WIF1—esophageal cancer	0.000142	0.000884	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—AKAP13—esophageal cancer	0.000141	0.000883	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—CXCL2—esophageal cancer	0.000139	0.00087	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—SST—esophageal cancer	0.000139	0.000866	CbGpPWpGaD
Guanabenz—ADRA2B—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.000139	0.000866	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CYP26A1—esophageal cancer	0.000138	0.000862	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GNG7—esophageal cancer	0.000137	0.000858	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—ELMO1—esophageal cancer	0.000135	0.000844	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—GHRL—esophageal cancer	0.000135	0.000844	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ALOX15—esophageal cancer	0.000135	0.00084	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—CREBBP—esophageal cancer	0.000132	0.000828	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—AKAP13—esophageal cancer	0.000132	0.000825	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000131	0.000816	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000131	0.000815	CbGpPWpGaD
Guanabenz—ADRA2C—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.00013	0.000809	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—ANXA1—esophageal cancer	0.000129	0.000808	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PDE4D—esophageal cancer	0.000129	0.000808	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—BLVRB—esophageal cancer	0.000129	0.000808	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—SLC52A3—esophageal cancer	0.000129	0.000808	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—ALDH2—esophageal cancer	0.000129	0.000804	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GSTO1—esophageal cancer	0.000128	0.000802	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—TPI1—esophageal cancer	0.000128	0.000802	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—NOS3—esophageal cancer	0.000127	0.000793	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—SST—esophageal cancer	0.000126	0.000786	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—GNG7—esophageal cancer	0.000123	0.000768	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ALDOB—esophageal cancer	0.000123	0.000768	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—GHRL—esophageal cancer	0.000123	0.000766	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GSTT1—esophageal cancer	0.000123	0.000765	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PFN1—esophageal cancer	0.000122	0.000763	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000122	0.000762	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CYP2A6—esophageal cancer	0.000121	0.000756	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PDE4D—esophageal cancer	0.000121	0.000755	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—NOS2—esophageal cancer	0.00012	0.000749	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—NOS3—esophageal cancer	0.000119	0.000741	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GAPDH—esophageal cancer	0.000118	0.00074	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CRABP1—esophageal cancer	0.000117	0.000733	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000116	0.000722	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—XIAP—esophageal cancer	0.000115	0.00072	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—GNG7—esophageal cancer	0.000115	0.000718	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—ENO1—esophageal cancer	0.000115	0.000717	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PTGS1—esophageal cancer	0.000115	0.000717	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PSME1—esophageal cancer	0.000113	0.000707	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PSME2—esophageal cancer	0.000113	0.000707	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GNG7—esophageal cancer	0.000112	0.000697	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CA1—esophageal cancer	0.00011	0.000687	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—SLC10A2—esophageal cancer	0.00011	0.000687	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ELMO1—esophageal cancer	0.00011	0.000686	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CTNNA1—esophageal cancer	0.000109	0.000681	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CXCL2—esophageal cancer	0.000108	0.000677	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—XIAP—esophageal cancer	0.000108	0.000673	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—CREBBP—esophageal cancer	0.000108	0.000672	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—AKAP13—esophageal cancer	0.000107	0.00067	CbGpPWpGaD
Guanabenz—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.000105	0.000657	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ALDH2—esophageal cancer	0.000105	0.000653	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CTNNA1—esophageal cancer	0.000102	0.000636	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PSME2—esophageal cancer	0.000101	0.000632	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PSME1—esophageal cancer	0.000101	0.000632	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CXCL2—esophageal cancer	0.000101	0.000632	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—ANXA1—esophageal cancer	0.000101	0.000629	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CA2—esophageal cancer	0.000101	0.000628	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GSTT1—esophageal cancer	9.95e-05	0.000622	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HIST1H2BM—esophageal cancer	9.9e-05	0.000619	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CYP2A6—esophageal cancer	9.84e-05	0.000614	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	9.83e-05	0.000614	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PDE4D—esophageal cancer	9.81e-05	0.000613	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—SST—esophageal cancer	9.8e-05	0.000612	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CYP1B1—esophageal cancer	9.76e-05	0.00061	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—EP300—esophageal cancer	9.66e-05	0.000603	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—NOS3—esophageal cancer	9.64e-05	0.000602	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—NOTCH3—esophageal cancer	9.55e-05	0.000597	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—GHRL—esophageal cancer	9.55e-05	0.000597	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PSME1—esophageal cancer	9.46e-05	0.000591	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PSME2—esophageal cancer	9.46e-05	0.000591	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—ANXA1—esophageal cancer	9.41e-05	0.000588	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—FBXW7—esophageal cancer	9.4e-05	0.000587	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PLCE1—esophageal cancer	9.35e-05	0.000584	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ADH7—esophageal cancer	9.35e-05	0.000584	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—GNG7—esophageal cancer	9.33e-05	0.000583	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ENO1—esophageal cancer	9.32e-05	0.000582	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PTGS1—esophageal cancer	9.32e-05	0.000582	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	9.24e-05	0.000577	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PSME1—esophageal cancer	9.19e-05	0.000574	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PSME2—esophageal cancer	9.19e-05	0.000574	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CYP19A1—esophageal cancer	9.18e-05	0.000573	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—SST—esophageal cancer	9.16e-05	0.000572	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—EP300—esophageal cancer	9.02e-05	0.000564	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—NOTCH3—esophageal cancer	8.92e-05	0.000557	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—GHRL—esophageal cancer	8.92e-05	0.000557	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—FBXW7—esophageal cancer	8.78e-05	0.000548	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—XIAP—esophageal cancer	8.75e-05	0.000546	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—NOTCH2—esophageal cancer	8.57e-05	0.000535	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—HMOX1—esophageal cancer	8.37e-05	0.000523	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CTNNA1—esophageal cancer	8.27e-05	0.000517	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CXCL2—esophageal cancer	8.22e-05	0.000514	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ADH1B—esophageal cancer	8.2e-05	0.000512	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—ABCB1—esophageal cancer	8.04e-05	0.000502	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—NOTCH2—esophageal cancer	8e-05	0.0005	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CYP1B1—esophageal cancer	7.93e-05	0.000495	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—TYMP—esophageal cancer	7.83e-05	0.000489	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PSME1—esophageal cancer	7.68e-05	0.00048	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PSME2—esophageal cancer	7.68e-05	0.00048	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ANXA1—esophageal cancer	7.65e-05	0.000478	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP26A1—esophageal cancer	7.62e-05	0.000476	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TGFBR2—esophageal cancer	7.6e-05	0.000475	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CYP19A1—esophageal cancer	7.45e-05	0.000466	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—SST—esophageal cancer	7.44e-05	0.000465	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ALOX15—esophageal cancer	7.43e-05	0.000464	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—EP300—esophageal cancer	7.33e-05	0.000458	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—GHRL—esophageal cancer	7.25e-05	0.000453	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NOTCH3—esophageal cancer	7.25e-05	0.000453	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—SMAD4—esophageal cancer	7.2e-05	0.000449	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—PIK3CA—esophageal cancer	7.15e-05	0.000446	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—FBXW7—esophageal cancer	7.13e-05	0.000445	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TGFBR2—esophageal cancer	7.1e-05	0.000443	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—TPI1—esophageal cancer	7.08e-05	0.000442	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTO1—esophageal cancer	7.08e-05	0.000442	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—TP53—esophageal cancer	6.91e-05	0.000432	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—HMOX1—esophageal cancer	6.8e-05	0.000425	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ALDOB—esophageal cancer	6.79e-05	0.000424	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—SMAD4—esophageal cancer	6.72e-05	0.00042	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—PIK3CA—esophageal cancer	6.68e-05	0.000417	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GAPDH—esophageal cancer	6.54e-05	0.000408	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ABCB1—esophageal cancer	6.53e-05	0.000408	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NOTCH2—esophageal cancer	6.5e-05	0.000406	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CRABP1—esophageal cancer	6.48e-05	0.000405	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—TP53—esophageal cancer	6.46e-05	0.000403	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GNG7—esophageal cancer	6.16e-05	0.000385	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—HIF1A—esophageal cancer	5.89e-05	0.000368	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ALDH2—esophageal cancer	5.77e-05	0.000361	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	5.77e-05	0.00036	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—KDR—esophageal cancer	5.63e-05	0.000352	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—HIF1A—esophageal cancer	5.5e-05	0.000343	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTT1—esophageal cancer	5.49e-05	0.000343	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	5.46e-05	0.000341	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP2A6—esophageal cancer	5.43e-05	0.000339	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	5.42e-05	0.000339	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.41e-05	0.000338	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CREBBP—esophageal cancer	5.37e-05	0.000336	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—NOTCH1—esophageal cancer	5.3e-05	0.000331	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—KDR—esophageal cancer	5.26e-05	0.000328	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—TP53—esophageal cancer	5.25e-05	0.000328	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PTGS1—esophageal cancer	5.15e-05	0.000321	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ENO1—esophageal cancer	5.15e-05	0.000321	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PSME2—esophageal cancer	5.07e-05	0.000317	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PSME1—esophageal cancer	5.07e-05	0.000317	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—NOTCH1—esophageal cancer	4.95e-05	0.000309	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—NOS3—esophageal cancer	4.81e-05	0.0003	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CREBBP—esophageal cancer	4.81e-05	0.0003	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—EGFR—esophageal cancer	4.73e-05	0.000295	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—PIK3CA—esophageal cancer	4.52e-05	0.000282	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CREBBP—esophageal cancer	4.49e-05	0.000281	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	4.47e-05	0.000279	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.43e-05	0.000277	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—EGFR—esophageal cancer	4.41e-05	0.000276	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PTGS2—esophageal cancer	4.4e-05	0.000275	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP1B1—esophageal cancer	4.38e-05	0.000273	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CREBBP—esophageal cancer	4.36e-05	0.000273	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—NOS3—esophageal cancer	4.31e-05	0.000269	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—KDR—esophageal cancer	4.27e-05	0.000267	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—PIK3CA—esophageal cancer	4.22e-05	0.000263	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP19A1—esophageal cancer	4.11e-05	0.000257	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—PIK3CA—esophageal cancer	4.1e-05	0.000256	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	4.03e-05	0.000252	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	4.02e-05	0.000251	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	4.02e-05	0.000251	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—NOS3—esophageal cancer	3.91e-05	0.000244	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	3.83e-05	0.000239	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	3.76e-05	0.000235	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—HMOX1—esophageal cancer	3.75e-05	0.000235	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.68e-05	0.00023	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—EP300—esophageal cancer	3.66e-05	0.000229	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	3.65e-05	0.000228	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ABCB1—esophageal cancer	3.6e-05	0.000225	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	3.59e-05	0.000224	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PTGS2—esophageal cancer	3.57e-05	0.000223	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	3.56e-05	0.000222	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	3.44e-05	0.000215	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	3.43e-05	0.000214	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	3.32e-05	0.000208	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—EP300—esophageal cancer	3.28e-05	0.000205	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	3.27e-05	0.000204	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	3.22e-05	0.000201	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	3.11e-05	0.000194	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—EP300—esophageal cancer	3.06e-05	0.000191	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	3.06e-05	0.000191	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—EP300—esophageal cancer	2.97e-05	0.000186	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MYC—esophageal cancer	2.85e-05	0.000178	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	2.79e-05	0.000174	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.72e-05	0.00017	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3CA—esophageal cancer	2.71e-05	0.000169	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	2.7e-05	0.000169	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MYC—esophageal cancer	2.67e-05	0.000167	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	2.61e-05	0.000163	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	2.61e-05	0.000163	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—EP300—esophageal cancer	2.48e-05	0.000155	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	2.42e-05	0.000151	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CREBBP—esophageal cancer	2.41e-05	0.00015	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TP53—esophageal cancer	2.34e-05	0.000146	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	2.26e-05	0.000141	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CA—esophageal cancer	2.2e-05	0.000137	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TP53—esophageal cancer	2.19e-05	0.000137	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MYC—esophageal cancer	2.17e-05	0.000135	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NOS3—esophageal cancer	2.16e-05	0.000135	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	2.12e-05	0.000132	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PTGS2—esophageal cancer	1.97e-05	0.000123	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	1.84e-05	0.000115	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TP53—esophageal cancer	1.78e-05	0.000111	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—EP300—esophageal cancer	1.64e-05	0.000102	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.21e-05	7.58e-05	CbGpPWpGaD
